Today: 10 June 2026
Browse Category

NASDAQ:IRWD 2 January 2026 - 5 January 2026

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% premarket Monday after Citizens upgraded the stock, citing eased pricing pressure on Linzess. The company last week cut Linzess’s list price by about 50% and forecast 2026 revenue of $450–$475 million. Shares closed up 26.7% Friday at $4.27, with trading volume surging to 85 million. Ironwood remains in a strategic alternatives review and plans a Phase 3 apraglutide trial in 2026.
5 January 2026
··
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Ironwood Pharmaceuticals shares jumped 26.7% Friday to $4.27 after the company issued 2026 guidance, forecasting total revenue of $450 million to $475 million and adjusted EBITDA above $300 million. The company expects 2026 Linzess U.S. net sales of $1.125 billion to $1.175 billion after lowering the drug’s list price on Jan. 1. Investors await a fourth-quarter update on the apraglutide Phase 3 trial and strategic review.
4 January 2026
·
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···

Stock Market Today

  • Darden Restaurants (DRI) Valuation Analysis Amid Mixed Share Performance
    June 10, 2026, 8:30 AM EDT. Darden Restaurants (DRI) shares traded around $200.91, up 1.3% last week and 2.4% over the month, yet down 4.2% year-over-year, reflecting mixed recent performance. The company, a major U.S. casual dining operator, shows a valuation score of 4 out of 6, indicating it is mostly undervalued. A Discounted Cash Flow (DCF) model projects an intrinsic value of $252.24 per share, suggesting the stock is approximately 20.3% undervalued based on future free cash flow estimates to 2035. This analysis may offer investors an opportunity amid ongoing consumer spending scrutiny and sector cost pressures.

Latest articles

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Shares Fall Again; Microsoft AI Cloud Agreement Still in Focus

10 June 2026
IREN plunged 8.73% to $54.02 Tuesday and slid another 3.72% premarket as investors weighed Wall Street’s bullish calls on its AI cloud buildout against a tech and crypto selloff; the stock’s fate now hinges on IREN’s ability to deliver Microsoft- and Nvidia-linked AI infrastructure on schedule, with the Microsoft contract at risk if timelines slip.
Archer Aviation Stock Falls After ARK Sale as ACHR Bulls Face Fresh eVTOL Test

Archer Aviation Stock Falls After ARK Sale as ACHR Bulls Face Fresh eVTOL Test

10 June 2026
Archer Aviation plunged 7.16% to $5.32 after ARK Invest dumped over 2.2 million shares across three ETFs, intensifying pressure on a stock already sensitive to funding and FAA certification risks; shares traded at $5.19 premarket as investors weighed cash burn, ongoing losses, and the urgent need for operational milestones before capital runs thin.
Tesla Drops Pre-Market as SpaceX IPO Buzz Puts Pressure on Musk Plays

Tesla Drops Pre-Market as SpaceX IPO Buzz Puts Pressure on Musk Plays

10 June 2026
Tesla slid 3% to $396.68 Tuesday and dropped another 1.26% premarket as SpaceX’s record $75 billion IPO, with over $250 billion in demand, gives investors a new Musk-linked bet, raising fears capital will rotate out of Tesla and other high-growth tech stocks just as Tesla’s next phase relies on heavy AI and robotaxi spending.
Go toTop